견적문의

SHENZHEN, CHINA & BERLIN--( / )--On the second day of CE China 2018, a focus was put on connecting China’s consumer electronics and home appliances businesses with the rest of the world by successful online distribution strategies. From 9.30 am to 4.30 pm over one thousand visitors of the E-Commerce Export Forum gained first-hand insights from manufacturers, brands and online retailers in 18 consecutive sessions. Exhibitors of CE China widely benefited from the additional attendees the Forum attracted to the third edition of CE China.

Among the global as well as Chinese companies presenting at the Forum, hosted by Shenzhen E-Commerce Service Center, were major market actors such as Amazon, eBay and Guangdong Pisen Electronics. In total, specialists from 16 companies shared their knowledge with the audience on how to grow cross-border business with e-commerce. They explained how to create a brand and achieve exposure for brands as well as brand products in foreign markets. The experts also provided hands-on information on different continental sales regions - including Africa, Middle East, West Asia and South America.

Further companies presenting were: Amanbo, DHgate, E-services Group, Globalegrow Electronic Commerce, Guangdong BESTEK E-Commerce, Hofan Group, JollyChic, Jumia&Linio&Daraz, Kilimall ,Lightinthebox, Shenzhen Thousandshores Technology, Sunvalley Group and Valuelink E-Commerce.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

INGELHEIM, GERMANY & INDIANAPOLIS, IND.--( / )--The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),[8] Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today. The approval has the 청운효자동맞고 오리지날 potential to advance the standard of care 종로4가동맞고 숏야상 for more than 47 million people in the 종로4가동맞고 여자봄야상 EU living with CKD,[2] and help relieve burden on healthcare systems by reducing the risk of all-cause hospitalization for people with CKD.[5,9,10] With existing indications in type 2 diabetes and heart failure,[6] empagliflozin could help manage the risks of cardio-renal-metabolic conditions, 종로4가동맞고 저지 which are often interconnected. Cardio-renal-metabolic conditions affect over 1 billion people worldwide.[7]

“We celebrate this significant milestone in the field of chronic kidney disease. 종로4가동맞고 부부성클리닉 CKD is a silent killer and prevention and early detection are crucial in the general population,” said Daniel Gallego, President of European Kidney Patients’ Federation. “This new 청운효자동맞고 예비부부교육 treatment option has the potential to further improve the management of cardiorenal metabolic syndrome and renal disease, offering SEXS “Wehope and improved quality of life for countless individuals living with CKD worldwide.”

The approval is based on results from EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in CKD to date, which showed a significant benefit of empagliflozin in reducing the relative risk of kidney disease progression or cardiovascular death by 28 percent vs. placebo in people with chronic 청운효자동맞고 아이비너였나봐 kidney disease (HR; 0.72; 95% CI 종로4가동맞고 0.64 to 0.82; P<0.000001 [absolute 종로4가동맞고 아이비트위터 risk reduction 3.8%]). The trial also demonstrated a statistically significant relative risk reduction in hospitalization for any cause by 14 percent vs. placebo (HR; 0.86; 95% CI 0.78 to 0.95; p=0.0025 [absolute risk reduction 4.4%]).[4,5] The overall safety data was generally consistent with previous findings, confirming the well-established 종로4가동맞고 safety profile of empagliflozin.[4,5] CKD doubles a person’s risk for hospitalization[3] and is a leading cause 강원랜드 Thedeath globally.[2] In the EU, hospitalizations account for up to 70 percent of total healthcare costs for people with CKD.[9,10]

“Living with chronic kidney disease can have a 종로4가동맞고 신민아화보 drastic impact on patients and their family’s lives. CKD not only affects individuals but also society overall due to the high economic burden to healthcare systems,” said Carinne Brouillon, Head 야동망고 “LivingHuman Pharma, Boehringer Ingelheim. “As we deepen our knowledge in interconnected cardio-renal-metabolic conditions, we are 종로4가동맞고 광동제약 very excited about the approval and the potential for empagliflozin to play an essential role in helping patients, their physicians and healthcare systems.”

“CKD is closely linked to other cardio-renal-metabolic conditions such as type 2 섹코 “CKDand heart failure - thus an integrated approach is vital for optimized treatment of these interconnected conditions. We look forward to continuing conversations with other regulatory bodies worldwide so that empagliflozin can be made available for as many people living with these conditions as quickly as possible,” continued 청운효자동맞고 러브젤 Leonard Glass, M.D., F.A.C.E., senior vice president, Diabetes & Obesity 종로4가동맞고 박민영나이 Global Medical Affairs, Lilly.

# 종로4가동맞고 가터벨트 ENDS 종로4가동맞고 유아라 #

써니넷 Pleaseclick here () 종로4가동맞고 갈라팬티 for ‘Notes to Editors’ and ‘References’ 청운효자동맞고 시티헌터강아지

View source version on businesswire.com:Korea Newswire distributes your news across every 종로4가동맞고 media channels through 청운효자동맞고 섹시화보 the industry’s largest press release distribution 종로4가동맞고 박한별털 network